Q2 2021 13F Holders as of 6/30/2021
-
Type / Class
-
Equity / Common Stock, $0.001 par value per share
-
Shares outstanding
-
59.6M
-
Number of holders
-
29
-
Total 13F shares, excl. options
-
24.7M
-
Shares change
-
+24.7M
-
Total reported value, excl. options
-
$614M
-
Value change
-
+$614M
-
Number of buys
-
29
-
Price
-
$24.95
Significant Holders of Janux Therapeutics, Inc. - Common Stock, $0.001 par value per share (JANX) as of Q2 2021
29 filings reported holding JANX - Janux Therapeutics, Inc. - Common Stock, $0.001 par value per share as of Q2 2021.
Janux Therapeutics, Inc. - Common Stock, $0.001 par value per share (JANX) has 29 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 24.7M shares
of 59.6M outstanding shares and own 41.52% of the company stock.
Largest 10 shareholders include RA CAPITAL MANAGEMENT, L.P. (8.67M shares), ORBIMED ADVISORS LLC (3.47M shares), JANUS HENDERSON GROUP PLC (2.67M shares), CITADEL ADVISORS LLC (1.89M shares), FMR LLC (1.84M shares), EcoR1 Capital, LLC (1.41M shares), BVF INC/IL (1.18M shares), DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) (700K shares), Samsara BioCapital, LLC (608K shares), and Logos Global Management LP (547K shares).
This table shows the top 29 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.